Glowing dye could help surgeons spot hidden brain cancer
NCT ID NCT07609472
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a single dose of FG001, a fluorescent dye, in 76 adults with newly diagnosed high-grade glioma. The dye is given before surgery and glows under a special light, helping surgeons tell tumor from healthy tissue during removal. The study checks how well the dye works and how much tumor is removed, with follow-up for six months after surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
FG001 (a fluorescent dye that glows under near-infrared light to help surgeons see tumor tissue)
What this could lead to
If it works, FG001 could help surgeons remove more of the tumor during surgery, potentially improving outcomes for people with high-grade glioma.
What could go wrong
This is an early-phase trial with only 76 people, so results may not apply to everyone. The dye is new and may not clearly distinguish tumor from healthy tissue in all cases.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH GRADE GLIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire, 03567, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Huntsman Cancer Institute, University of Utah
Salt Lake City, Utah, 84112, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UPMC Presbyterian Hospital
Pittsburgh, Pennsylvania, 15213, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Miami
Miami, Florida, 33125, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Texas Medical Branch
Galveston, Texas, 77555, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact